Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.

Abstract

Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.

• Authors: Pierre Quartier, Olivier Tournilhac, Christine Archimbaud, Leila Lazaro, Carine Chaleteix, Pascale Millet, Hélène Peigue-Lafeuille, Stéphane Blanche, Alain Fischer, Jean-Laurent Casanova, Philippe Travade, Marc Tardieu
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 36 Issue 3 Pg. e47-9 (Feb 01 2003) ISSN: 1537-6591 [Electronic] United States
• PMID: 12539090 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Antineoplastic Agents
• Rituximab

Topics

• Antibodies, Monoclonal (adverse effects)
• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20 (immunology)
• Antineoplastic Agents (adverse effects)
• Child
• Humans
• Meningoencephalitis (chemically induced)
• Middle Aged
• Rituximab